Home About us Contact
|
Home About us Contact | ||
|
|
||
Scientific Programme (scientific + programme)
Selected AbstractsICS-IUGA 2010 Scientific Programme, Wednesday 25th August 2010NEUROUROLOGY AND URODYNAMICS, Issue 6 2010Article first published online: 19 JUL 2010 First page of article [source] Safety pharmacology in the nonclinical assessment of new medicinal products: definition, place, interest and difficultiesFUNDAMENTAL & CLINICAL PHARMACOLOGY, Issue 2 2002Jean-Roger Claude Until the year 2000 there was no internationally-accepted definition for the terms used in nonclinical pharmacology (primary, secondary pharmacodynamics, discovery, safety pharmacology, etc). Now, after ICH5 (San Diego, November 2000), a harmonisation of the nomenclature is adopted: safety pharmacology is defined as the studies that investigate the potential undesirable pharmacodynamic effects of a medicinal product on physiological functions in relationship to exposure. Consequently, safety pharmacology studies are a part of the safety assessment for a new product, in the same way than toxicological studies, and a basic battery of tests (core battery) has to be conducted prior to the first administration to humans. Safety pharmacology studies are of peculiar interest: they show a good predictive potential for humans, they do not require a large number of laboratory animals, long-term studies, large amount of products and they are more dynamic and more flexible than toxicological studies. Nevertheless, many difficulties occur for the implementation in industry, related to practical and/or scientific problems: location of the studies, routine activity for the pharmacologists, sometimes difficulties in the relationship between toxicologists and pharmacologists, adaptation to the GLP requirements, elaboration of an early relevant scientific programme, necessity to go to contract-labs or to academic research for unusual or for up to date methods, etc. To conclude, a retrospective timetable of the regulatory evolution for the last 10 years will be provided, as an illustration of the worldwide progress in the concept of `harmonisation' for the assessment of new medicinal products. [source] Clinical controversies at Congress 2001JOURNAL OF SMALL ANIMAL PRACTICE, Issue 3 2001Article first published online: 28 JUN 200 The addition of some controversial topics to the scientific programme of Congress 2001 should add some spice to the proceedings. Jackie Wilson, of the Congress Committee, previews three themes on issues at the forefront of many practitioners' minds [source] The birth of the European Crystallographic Committee (ECC) and of the European Crystallographic Meetings (ECMs)ACTA CRYSTALLOGRAPHICA SECTION A, Issue 1 2010André Authier At ECM25, held in Istanbul, Turkey, on 16,21 August 2009, the 25th anniversary of the European Crystallographic Meetings was celebrated. In this article, it is recalled how the idea of coordinating international meetings on crystallography in Europe was put forward at a meeting held in Manchester, UK, in April 1971, and it is explained how the European Crystallographic Committee was established for that purpose during the Ninth IUCr Congress in Kyoto, in 1972. The organization of the first European Crystallographic Meeting, ECM1, held in Bordeaux, France, in 1973, is briefly described and the evolution of the main topics of the scientific programme from that time to ECM25 is commented upon. [source] | ||||||||||